Exabis Library
Welcome to the e-CCO Library!
DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP026: Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP026: The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient-reported outcome measures PRO-2 and ClinPRO in moderate-to-severe active ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP027: Large-scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP028: Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP028: Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP029: Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP02: Increasing incidence of Inflammatory Bowel Disease in a high prevalence country: A nationwide study in Finland
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP02: Single cell RNA sequencing of Ulcerative Colitis and Crohn's Disease tissue samples informs the selection of Triggering Receptors Expressed on Myeloid Cells 1 (TREM1) as a target for the treatment of Inflammatory Bowel Diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP02: Supplementation with butyrate producing bacteria reduces tumour load in a mouse model of colitis-associated cancer
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP02: αEβ7 positive γδ T cells are associated with mucosal healing in Ulcerative Colitis and have a homeostatic immunophenotype
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP03 The impact of elemental diet on the human gut microbial structure and intestinal metabolites
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's disease: a dual centre “real world” study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM